Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Troglitazone in PPARγ–TAM Assay Design
2026-08-13
Explore how Troglitazone, a PPARγ agonist with PPARα activity, can be positioned in metabolic and tumor-myeloid assays without confusing receptor activation with direct SPP1 inhibition. This guide translates recent SPP1-screening innovation into rigorous experimental decisions.
Mithramycin A: From DNA Binding to Translation
2026-08-13
Mithramycin A is an anticancer antibiotic that converts G-C-rich DNA recognition into a research strategy for studying transcription, c-myc regulation, and myeloid differentiation. This thought-leadership guide connects mechanistic assay design with translational decision-making while clarifying what cardiac signaling studies can—and cannot—tell cancer researchers.
GI 254023X: ADAM10 Inhibitor Workflow Guide
2026-08-12
GI 254023X enables selective ADAM10 pathway perturbation across Jurkat signaling, endothelial barrier, and preclinical toxin-injury models. This workflow-focused guide emphasizes target engagement, paired functional readouts, formulation control, and evidence-aware interpretation.
Bay 11-7821 (BAY 11-7082) in Cancer Immunity
2026-08-12
Bay 11-7821 (BAY 11-7082) offers a practical way to test whether NF-κB activity links radiotherapy-driven inflammation, macrophage activation, and CD8+ T-cell immunity. This thought-leadership guide translates recent abscopal-effect findings into a disciplined workflow for inflammatory signaling pathway research, cancer research, and apoptosis regulation studies.
Redox-Responsive Peptide Coacervates for mRNA Delivery
2026-08-11
The reference study introduces HBpep-SS4, a chemically defined peptide coacervate whose disulfide chemistry is encoded within its primary sequence to couple mRNA protection with glutathione-triggered intracellular release. The system encapsulated diverse RNA cargos, supported efficient delivery and genome editing, and provides a useful design framework for studying how phase separation, cellular uptake, and reductive disassembly influence mRNA function.
Ceftolozane/Tazobactam Against Resistant Gram-Negatives
2026-08-11
The reference paper reviews how ceftolozane/tazobactam combines a potent antipseudomonal cephalosporin with β-lactamase inhibition to address difficult gram-negative infections. Its analysis integrates mechanism, resistance, pharmacokinetics, pharmacodynamics, clinical trials, and safety, while showing why activity against Pseudomonas aeruginosa and selected ESBL-producing Enterobacteriaceae is clinically meaningful.
α-Bungarotoxin: From Blockade to Translation
2026-08-10
α-Bungarotoxin is more than a receptor antagonist: it is a causal tool for testing whether α7 nicotinic acetylcholine receptor signaling drives biological outcomes. This article connects nicotinic receptor blockade with recent evidence on placental necroptosis, offering translational researchers a framework for experimental design, model selection, and mechanistic confidence.
Hypoxia, Choroid Plexus, and Cognitive Impairment
2026-08-09
This mouse study identifies choroid plexus barrier disruption as a mechanistic link between simulated high-altitude hypoxia and cognitive dysfunction. Its central model connects abnormal AMPK signaling and oxidative stress with M1 macrophage polarization, blood–cerebrospinal fluid barrier failure, and impaired CNS function.
HRP Goat Anti-Rabbit IgG (H+L) Antibody Guide
2026-08-08
HRP Goat Anti-Rabbit IgG (H+L) Antibody is an affinity-purified, HRP-labeled secondary reagent for detecting rabbit IgG in Western blotting, ELISA, IHC, and immunocytochemistry. It is intended for research workflows requiring rabbit-primary-antibody detection and should not be used as a diagnostic or medical reagent; assay-specific dilution and substrate conditions require local optimization.
Dextran sulfate sodium salt: Colitis Workflow Guide
2026-08-07
Build more reproducible mouse models of epithelial injury with Dextran sulfate sodium salt and a workflow that separates damage induction from repair biology. The guide connects DSS dosing, intake monitoring, and epithelial readouts to the GPR35–KLF5 repair circuitry described in recent ulcerative colitis research.
Reliable Cell Viability with Cell Counting Kit-8 (CCK-8): In
2026-08-07
This article explores real-world laboratory challenges in cell viability and cytotoxicity assays, critically evaluating the Cell Counting Kit-8 (CCK-8) (SKU K1018). Using scenario-driven Q&A, we demonstrate how CCK-8 delivers reproducible, sensitive results for cancer research and beyond, referencing both published evidence and workflow needs.
Octenidine Dihydrochloride: Applied Antiseptic Research Work
2026-08-06
Octenidine dihydrochloride empowers antimicrobial research with robust, reproducible workflows targeting microbial membrane disruption. This guide translates structure-activity innovations and practical troubleshooting into advanced, laboratory-ready protocols, making APExBIO’s compound a critical tool for next-generation antiseptic studies.
Quercetin as a Multi-Target PI3K Inhibitor in Ferroptosis an
2026-08-06
Explore how Quercetin, a potent PI3K inhibitor, uniquely bridges ferroptosis suppression and apoptosis induction in cancer and liver research. This in-depth analysis offers new perspectives on mechanistic workflows and practical protocol guidance.
PR-619: A Versatile Deubiquitylating Enzymes Inhibitor for A
2026-08-05
PR-619 empowers researchers to dissect the ubiquitination pathway with precision, enabling reliable accumulation of ubiquitinated proteins for autophagy, cancer, and neurodegeneration studies. Its broad-spectrum, reversible inhibition profile and robust performance in cell-based assays distinguish it from traditional proteasome inhibitors.
GI 254023X: Unraveling ADAM10 Inhibition for Translational R
2026-08-05
Explore GI 254023X, a potent ADAM10 inhibitor, in the context of translational research. This article uniquely bridges mechanistic depth, practical protocol guidance, and critical insights from recent neurodegeneration studies.
8040 records 12/536 page Previous Next First page 上5页 1112131415 下5页 Last page